The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma
about
A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cellsSH2B1beta adaptor is a key enhancer of RET tyrosine kinase signalingInteraction of SH2-Bbeta with RET is involved in signaling of GDNF-induced neurite outgrowthThe RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsShc and Enigma are both required for mitogenic signaling by Ret/ptc2.Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascadeThe neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cellsNovel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiationThe role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptorMicrosomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.RET PLCĪ³ phosphotyrosine binding domain regulates Ca2+ signaling and neocortical neuronal migration.Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene.A Drosophila model of multiple endocrine neoplasia type 2.Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitizationThe RET proto-oncogene: a molecular therapeutic target in thyroid cancer.Regulation of neural development by glial cell line-derived neurotrophic factor family ligands.The RET-glial cell-derived neurotrophic factor (GDNF) pathway stimulates migration and chemoattraction of epithelial cells.RET is a potential tumor suppressor gene in colorectal cancer.Brain ischemia downregulates the neuroprotective GDNF-Ret signaling by a calpain-dependent mechanism in cultured hippocampal neurons.Structure and physiology of the RET receptor tyrosine kinase.Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasiaSplicing variants impact in thyroid normal physiology and pathological conditions.Central role of RET in thyroid cancer.Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.Thyroid C-Cell Biology and Oncogenic Transformation.Differential recruitment of E3-ubiquitin ligase complexes regulates RET isoform internalization.Ape1/Ref-1 Stimulates GDNF/GFRalpha1-mediated Downstream Signaling and Neuroblastoma Proliferation.RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.Deciphering adaptor specificity in GFL-dependent RET-mediated proliferation and neurite outgrowth.Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase.NGF augments the autophosphorylation of Ret via inhibition of ubiquitin-dependent degradation.RET and neuroendocrine tumors.Differential effects of glial cell line-derived neurotrophic factor and neurturin in RET/GFRalpha1-expressing cells.Activation of c-Jun amino-terminal kinase by GDNF induces G2/M cell cycle delay linked with actin reorganization.The long and short isoforms of Ret function as independent signaling complexes.Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase.Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival.RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
P2860
Q24291278-F31D227A-4E9D-4125-9C45-3CB667B5BDB9Q24304330-5CDB5529-780B-407B-9EC7-CC0EC8984A05Q24311524-3F8D258E-4DED-413A-BE58-2EF92E58DEE7Q24519206-D886C56F-67B4-4969-891D-341FBF93F522Q24533621-33A8498D-67B0-44D3-A769-6D47AFCC2CC6Q24550950-121ADF6A-A87B-41E8-8B9D-5825E6EB34FEQ24676241-0781EA84-4C99-4E99-8F8A-ADE899E47451Q24685580-0277E56A-D7EE-4067-AAF3-72419AC28527Q28678514-D4C2F076-41A2-4C8E-A923-10CE8F7A7239Q33193878-85B2857F-905F-47A7-9751-620710790269Q34080215-3D8377C5-6F46-4CE4-B527-AEC96C465066Q34166301-6CB03D2B-0AA9-49F5-9EE1-E145CDF4A0BFQ34495337-D1AA3189-236B-4E20-B0A8-A8017583AA92Q34589821-5D76A00A-CE0E-4F1F-A707-67756D1DD303Q34809183-4BC3031B-0E8D-4A0E-AC5C-914A8AF4E81EQ36072495-56CB850D-8E6C-4F0F-ADB7-688D81E665C4Q36081834-946568D2-5463-4030-96AD-5185286A4806Q36290601-BA9AFD8D-A313-4C5B-A19E-55D2577A3952Q36301488-349ABFA4-681E-4240-8D62-6350979ADE73Q36347279-5FAC7A48-B688-4E3A-BBF8-DE27E7603231Q36555201-2367D5F8-C0AC-43E4-8F78-238137D22A85Q36613519-7468695E-1293-4B91-8FAC-C81172BDE6F1Q37493754-ED492F0D-0C75-443C-BA2C-1C82C5D7774EQ37628520-A69C8D9F-A8C6-4994-A754-CCF2F56B2F7EQ38167995-C1B039D6-AED3-4089-A634-F9C64F414C0AQ38425184-C44944A8-DF2D-49D8-8408-4D954F366B53Q38614485-1AA7A9B7-F9A1-4CA8-A9E9-E0BE028056FAQ38631763-38E9E391-31DB-4728-A70D-6FC98F745D7BQ39774211-AAF412A2-4DED-46D0-8C8B-D2FC7E0269BFQ39901958-0DA32695-9C5D-49F6-A951-2DFA7F0BEE00Q40100594-3BD7BE07-7376-4DD1-AE62-E4D12F475536Q40153841-8CFFDC60-EDA7-4AA5-9439-BCC41B38344AQ40180500-86FA17ED-5FDA-4430-8FAA-EC53242FEEC7Q40221010-048B4493-1F06-404C-B454-6C62AEF154D2Q40349992-12CB393C-F2D2-4EE6-9F83-5CC5BB22E7B6Q40407182-085FC385-63F5-40E9-ADEE-95725DA6AFEFQ40721459-47636E46-5DCC-4B9B-A27C-BE8CE7CAAF04Q40745449-2E585E14-681A-46E3-A439-803D3A5DFB6AQ40768044-188D0472-ADA2-4DED-BA01-E9293B17CC10Q40769254-8630660F-DF55-4623-8CA0-024E9BB7CF9C
P2860
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma
description
1996 nĆ® lÅ«n-bĆ»n
@nan
1996 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ”ÕµÕ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
1996 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ“Õ”ÕµÕ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
1996幓ć®č«ę
@ja
1996幓č«ę
@yue
1996幓č«ę
@zh-hant
1996幓č«ę
@zh-hk
1996幓č«ę
@zh-mo
1996幓č«ę
@zh-tw
1996幓č®ŗę
@wuu
name
The full oncogenic activity of ...... site for phospholipase Cgamma
@ast
The full oncogenic activity of ...... site for phospholipase Cgamma
@en
The full oncogenic activity of ...... site for phospholipase Cgamma
@en-gb
The full oncogenic activity of ...... site for phospholipase Cgamma
@nl
type
label
The full oncogenic activity of ...... site for phospholipase Cgamma
@ast
The full oncogenic activity of ...... site for phospholipase Cgamma
@en
The full oncogenic activity of ...... site for phospholipase Cgamma
@en-gb
The full oncogenic activity of ...... site for phospholipase Cgamma
@nl
prefLabel
The full oncogenic activity of ...... site for phospholipase Cgamma
@ast
The full oncogenic activity of ...... site for phospholipase Cgamma
@en
The full oncogenic activity of ...... site for phospholipase Cgamma
@en-gb
The full oncogenic activity of ...... site for phospholipase Cgamma
@nl
P2093
P50
P356
P1476
The full oncogenic activity of ...... site for phospholipase Cgamma
@en
P2093
C Battistini
M G Borrello
M G Rizzetti
M T Radice
P Mondellini
P304
P356
10.1128/MCB.16.5.2151
P407
P577
1996-05-01T00:00:00Z